In order to produce antibodies for the radioimmunoassay of cholecystokinin the following animals were immunized: 10 rabbits and 3 guinea pigs with cholecystokinin 1-33 coupled to bovine serum albumin, 9 rabbits and 2 guinea pigs with uncoupled cholecystokinin 1-33, 5 rabbits with cholecystokinin 10-20 coupled to bovine serum albumin and 4 rabbits with sulphated cholecystokinin 26-33 coupled to bovine serum albumin. The titer, the binding energy and the specificity of the antibodies were evaluated. Cholecystokinin 1-33, coupled to [ 125
von 1:52000 aufwies. Die Affinitätskonstante dieser 6 Antikörper lag zwischen K = 2,0 x 10 10 und 72,3 x l O 10 1/mol. Ein Antikörper war spezifisch für alle sulfatierten Cholecystokinine, während die anderen 5 Antikörper spezifisch für die großmolekularen Cholecystokinine waren. Bei den mit Cholecystokinin 1-33 immunisierten Meerschweinchen und bei den mit Cholecystokinin-Fragmenten immunisierten Kaninchen waren die Antikörpertiter kleiner als 1:500.
Introduction
. \
Cholecystokinin is one of the classical gut hormones (1) . This peptide hormone stimulates gall bladder contraction and secretion of enzymes from the pancreas (2, 3) . In extracts of gut and brain cholecystokinin was found to be present in several molecular forms (4) . Originally cholecystokinin was isolated from acid extracts of hog small intestine äs a basic molecule containing 33 amino acid residues (choleĉ ystokinin 1-33) with the chemical structure LysAla-Pro-Ser-Gly-Arg-Val-Ser-Met-Ile-Lys-AsnLeu-Gln-Ser-Leu-Asp-Pro-Ser-His-Arg-Ile-SerAsp-Arg-Asp-Tyr(SO 3 )-Met-Gly-Trp-Met-AspPhe (4, 5) . A molecular form extended at the NH 2 -terminus by 6 amino acid residues, Tyr-Ile-Gln-GlnAla-Arg (cholecystokinin 1-39), was described some years later (6) . Recently, it was shown that in neutral extracts of sheep brain a smaller molecular form containing 8 amino acid residues (cholecystokinin 26-33) predominates (4, 7) .
Even though the first radioimmunoassay of cholecystokinin was reported äs early äs 1969 (8) , only few radioimmunoassays have so far been developed, despite much effort. Several factors contribute to the difficulties in developing a reliable radioimmunoassay for cholecystokinin:
1. difficulties in producing antibodies due to the low immunogenicity (9), 2. an unacceptably high degree of cross-reactivity of COOH-terminal antibodies with gastrin, because both peptides share the same COOH-terminal pentapeptide sequence, 3 . suspected species differences in the NHi-terminal sequence of cholecystokinin 1-33 resulting in antibodies feacting with porcine cholecystokinin but not with cholecystokinin from other species (10, 11), 4. availability of only limited amounts of pure cholecystokinin, and 5. difficulties in preparing immuno^reactive cholecystokinin labels. It has been shown that the conventional oxidizing labelling methods, such äs the chloramine T methöd and the lactoperoxidase method, result in cholecystokinin labels of poor immunoreactivity, probably düe to the deleterious effects of oxidation of the methionine residues in cholecystokinin (12) . Recently, the la·? belling problem has been overcome by using a non-oxidizing labeÜing inethod. Using [ 125 I]hydroxyphenylpropionic aäd-$ucänimide ester (Bolton-Hunter reagent) Rehfeld was able to produce highiy immunoreactive cholecystokinin 1-33 labels, and he suggested that cholecystokinin 1-33 was a good immunogen (12, 13) . In this report we present our experience with the production of antibodies to cholecystokinin in rabbits and guineä pigs. Furthermore, the titer, the binding energy and the specificity of the antibodies were evaluated in radioimmunoassäys using BoltonHunter labelled cholecystokinin 1-33. In addition, we have measured cholecystokinin concenträtions in extracts of human and hög üpper small intestine and in human plasma after ingestion of fat, using radioimmunoassays employing an antibody specific for sulphated forms of cholecystokinin and an antibody specific for large forms of cholecystokinin. and 7%, The specific activity of the label, deterrained according to Stadil & Rehfeld (14) , ranged from 8.1 to 14.7 ΜΒς/μ § (219 to 398 nCi/[ig) (n = 8). When the label was rechromatographed on SP-Sephadex C 25 using a 0.05 to 1.0 mol/l acetic acid gradient, the radioactivity eluted s a single peak.
Materials and Methods

Peptides
Incubation conditions
Antibody titers were determined s follows. The assays were set up in plastic tubes in an ice bath using 0.02 mol/l sodium barbital buffer pH 8.4 containing 0.03 mmol/1 human serum albumin and 0.06 mmol/1 sodium ethylmercurithiosalicylate. The 2.2 ml incubation volume consisted of 1.0 ml of approximately 2000 counts/ min label, 0.2 ml Standard solution, and 1.0 ml diluted antiserum. The tubes were incubated for 96 hours at 4 °C To determine the binding energy and cross-reactivity of the antibodies a pre-equilibrium method was used. 0.2 ml Standard solution was incubated with 0.1 ml diluted antiserum for 72 hours at 4 °C. After addition of approximately 2000 counts/min Bolton-Hunter labelled chole 1 -cystokinin 1-33 in 0.2 ml buffer, the mixture was incubated for another 48 hours at 4 °C. All dilutions in this pre-equilibrium assay were made in 0.05 mol/l sodium phosphate buffer pH 7.4 containing 0.08 mmol/1 human serum albumin and 0.06 mmol/1 sodium ethylmercurithiosalicylate.
Separation procedure Antibody-bound radioactivity was separated from free label by addition of a 1.5 ml Suspension of 0.05 mol/l sodium phosphate buffer pH 7.4 containing 25 mg activated charcoal, 2.5 mg dextran T 70 and 16 mg bovine serum albumin. The tubes were vortexed and immediately centrifuged (3000 g for 10 minutes). In the double-antibody Separation technique l ml of 1:20 diluted sheep anti-rabbit immunoglobulin was added to the tube and incubated for 4 to 8 hours at 4 °C before centrifugation. Both the supernatant and the pellet were counted in an automatic γ-scintillation counter.
Tryptic cleavage 230 μιηοΐ/ΐ 99% pure cholecystokinin 1^33 was incubated with 5 g/l trypsin for 60 minutes at 37 °C. The action of trypsin was terminated by boiling for 10 minutes. The completeness of cleavage of cholecystokinin 1-33 to the COOH-terminal octapeptide (sulphated cholecystokinin 26-33) was assessed by gel filtration of cholecystokinin 1-33 before and after trypsinization on a Sephadex G 50 SF column, 200 x 1.5 cm, using 0.02 mol/l sodium barbital buffer pH 8.4 s eluant at 4 °C. The eluate was measured by radioimmunoassay using a COOH-terminal cholecystokinin antibody and 125 I labelled non-sulphated cholecystokinin 26-33 (15).
Tissue extraction
Pieces of freshly obtained human (n = 3) and hog (n = 3) upper small intestine were extracted in boiling water (l g/10 ml) for 10 minutes. After homogenization and centrifugation the supernatant was decanted and the pellet was re-extracted in 0.5 mol/l acetic acid (l g/10 ml) for 10 minutes. After centrifugation the supernatant was added to the supernatant of the aqueous extraction, rapidly frozen, lyophilized, dissolved in 0.05 mol/l sodium phosphate buffer and measured by radi immunoassay.
Measurement of cholecystokinin in plasm
Blood samples were collected in ice-chilled glass tubes containing 2 g/l ethylenediaminetetraacetate (EDTA). After centrifugation the plasm was frozen at -20 °C. Cholecystokinin was extracted from plasm by addition of 2 volumes of 960 ml/ί ethanol to l volume of plasm . After mixing and centrifugation tHe supernatant was evaporated to dryness under a stream f nitrogen at 37 °C.
The dried supernatant was reconstituted in assay buffer and 200 μΐ were incubated with 100 μΐ diluted antiserum for 72 hours at 4 °C. After addition of 200 μΐ labelled cholecystokinin 1-33 containing approximately 2000 counts/min and incubation for another 20 hours at 4 °C, free and antibody-bound peptide were separated and counted in a γ-scintillation counter. Cholecystokinin 1-33 was used s Standard, and antibodies 1703 and T204 s antisera. 0.05 mol/l sodium phosphate buffeV pH 7.4 containing 0.08 mmol/1 human serum albumin and 0.06 mmol/ϊ sodium ethylmercurithiosalicylate was used s assay buffer. Recovery of cholecystokinin added to hormone-free plasm was 85.4 ± 2.0% (mean ± SD; n = 11). Separation using plasma-coated charcoal or the double-antibody solid phase technique gave identical results. The detectipn limit of the assays was between 0.5 and 1.0 pmol/1 plasm . Intra-assay Variation ranged from 4.6-8.4% and inter^assay Variation from 11.3^15.4%.
Human studies
After an overnight fast 6 normal s bjects (4 males and 2 females; mean age 30 years, r nge 23^38 years) ingested 60 rfil corn oil. Blood samples were obtained at -5, 0, 5, 10, 15, 20, 30, 40, 50, 60, 75 and 90 minutes.
Statistics
Results were expressed s mean ± SEM, unless otherwise stated. Studenfs t-test for paired data was used for analysis of the plasm cholecystokinin results.
Results
The titers of the antibodies after the second, third and fourth immunization are presented in table 2. Antibodies with titers greater than 1:10000 were not detected after the second immunization, while after the third immunization 3 anijnals and after the fourth immunization 6 animals had produced antibodies with titers of more than 1:10000. Of the 10 rabbits immunized with albumin-coupled cholecystokinin 1-33, 5 had antibody titers of more than 1:10000 ranging firorn 1:22500 to 1:80000. Of the 9 rabbits immunized with uncoupled cholecystokinin 1^33, one produced a high titer antibody, 1:100000 after the third arid 1:52000 after the fourth immunization. Immunization with synthetic cholecystokinin fragments (cholecystokinin 10-20 and sulphated cholecystokinin 26-33) did not fesult in antibodies detectabie in radioimmunoassays employing BoltonHunter labelled cholecystokinin 1-33. None of the guinea pigs produced cholecystokinin antibodies with titers of more than 1:500.
In radioimmunoassays using Bolton-H nter labelled cholecystokinin 1-33 the binding eneijgy of 6 high titer antibodies after the fourth immunization and of one antibody after the third immunization (1703) were determined. The affinity constants indicating the binding energy between the antibodies and cholecystokinin 1-33 (16) (table 3) . Binding to sulphated gastrin 1-17 and sulphated gastrin 1-34 was low, while binding to non-sulphated forms of cholecystokinin or gastrin and to unrelated peptides was absent. All 6 antibodies did not only bind to porcine cholecystokinin, but also to cholecystokinin in human tissue extracts. The increases in plasma cholecystokinin were similar for both antibodies (fig. 4 ).
Discussion
This study shows that cholecystokinin 1^-33 is an excellent immunogen when Bolton-Hunter labelled cholecystokinin l-33 is employed äs the rädioactive peptide in radioimmunoassays. immunization of rabbits with albumin-coupled cholecystokinin 1^33 produced high titer antibodies in 5 of 10 animals, while immunization of 9 rabbits with üricoüpled cholecystokinin 1-33 produced high titer antibodies in one animal. Four of these antibodies had high binding energies with affinity constants of more than 5 x 10 11 1/mol. No antibodies Were obtained in guin ea pigs immunized with uncoupled or albumincoupled cholecystokinin 1-33 or in rabbits immunized with albumin-coupled cholecystokinin fragments. Therefore, immunization of rabbits with albumin-coupled cholecystokinin 1-33 seems to be the most suitable method to prodüce antibodies for the radioimmunöassäy of cholecystokinin. In contrast to a previous report (9), our results confirm Rehfeld's finding that cholecystokinin 1-33 has good immunogenic properties (12) . It has been claimed by Rehfeld that cholecystokinin 1-33 is a good immunogen provided cholecystokinin is not exposed to oxidation during the labelling procedure (12) . However, high titer cholecystokinin antibodies have been described in radioimmunoassays using cholecystokinin 1-39 or nonsulphated cholecystokinin 26-33 iabelled with n *I by the chloramine T method (15, 17, 18) . On the other hand, it seems to be extremely difficult to raise high titer antibodies against cholecystokinin 1-33 when an oxidizing labelling method is used. Thompsotfs group has produced an antibody against cholecystokinin 1-33 which binds 25 to 35% of cholecystokinin 1-39, labelled with 125 I by the chloramine T method, at a final dilution of 1:100000 (17) . In most radioimmunoassays using cholecystokinin 1-33 or cholecystokinin 1-39, labelled by the chloramine T method, the titers of the antibodies are extremely low (8, 10, 19, 20, 21) . From the present study it carmot be concluded whether the excellent immunogenicity of cholecystokinin 1-33 in our hands is attributable to the immunization schedule employed or to the use of a non-oxidizing labelling method. Using BoltonHunter labelled cholecystokinin 1-33, Rehfeld reported cholecystokinin antibodies with a titer between 1:10000 and 1:30000 in 3 of 10 rabbits immunized with albumin-coupled cholecystokinin 1-33 (12) . However, none of these antibodies had affinity constants above 5 x 10 U 1/mol. Byrnes et al. (22) immunized 16 rabbits with albumin-coupled cholecystokinin 1-33 and only one of the animals produced an antibody with a titer of 1:10000. When Bolton-Hunter labelled cholecystokinin 1-33 was used in the assay the affinity constant was 5.5 x l O 11 1/mol (22) . Rehfeld suggested that cholecystokinin 1-33 is particularly immunogenic in guinea pigs (12) . Twelve of 30 animals produced antibodies with titers between 1:10000 and 1:50000. Three of these antibodies had affinity constants of iriore than 5 x 10 11 1/mol. While Rehfeld (12) and Byrnes et al. (22) did not find antibody titers higher than 50000, we found this level of titers in 4 rabbits. Some authors advocate an immunization schedule in which crude cholecystokinin 1-33 is used for the initial immunizations followed by 99% pure cholecystokinin 1-33 for the final immunization (17) . In our study excellent antibodies were obtained after immunization with 30% pure cholecystokinin 1-33. 99% pure cholecystokinin 1-^33 is difficult to obtain and our data do not support the need for highly purified cholecystokinin 1-33 äs immunogen.
The high binding enefgy of 4 antibodies (K > 5 x l O 11 1/mol) in the present study was reflected in the high sensitivity of the radioimmunoassays. The dose of cholecystokinin 1-33 at which the binding between label and antibody was inhibited by 50% (iD 50 ) ranged from 2.8 to 5.0 pmol/1. The detection limit of these assays was between 0.5 and 3 pmol/1 sample. These assays were extremely sensitive and they were able to measure the very low concentrations of cholecystokinin present in the circulation (fig. 4) .
Five antibodies bound to cholecystokinin 1-33 and cholecystokinin 1-39, but not to synthetic cholecystokinin fragments (sulphated and non-sulphated cholecystokinin 26-33, cholecystokinin 30-33, cholecystokinin [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] or cholecystokinin fragments prepared by trypsinization of cholecystokinin 1-33 (cholecystokinin 1-6, cholecystokinin 7-11, cholecystokinin 12-21, cholecystokinin 22-25, sulphated cholecystokinin 26-33). Go et al. (10) and Straus & Yalow (11) produced antibodies to cholecystokinin 1-33 which reacted only with porcine cholecystokinin, but not with cholecystokinin from other species. They suggested that there might be species differences in the structure of cholecystokinin 1-33 at the NHb-terminus. Our antibodies not only bound to porcine cholecystokinin but also to human cholecystokinin. Since the antibodies do not cross-react with gastrin or with structurally unrelated peptides, these antibodies are extremely suitable for quantifying large forms of cholecystokinin in blood and tissue. One antibody (T204) seems to be directed to the sulphated tyrosine region of the molecule. It binds to large cholecystokinin and cholecystokinin fragments containing the sulphated tyrosine region (cholecystokinin 1-39, cholecystokinin 1-33, caerulein, sulphated cholecystokinin 26-33, trypsinized cholecystokinin 33) but not to unsulphated cholecystokinin fragments (non-sulphated cholecystokinin 26-33, cholecystokinin 10-20, cholecystokinin 30-33). Since the binding to sulphated gastrin 1-17 and sulphated gastrin l-34 is low and the binding to non-sulphated gastrin 1 -17 and gastrin 1-34 and structurally unrelated peptides is absent, this antibody is suitable for quantifying the sulphated forms of cholecystokinin in blood and tissue. Since only sulphated molecular forms of cholecystokinin possess biological activity, this assay will quantify only the biological active forms of cholecystokinin.
In conclusion, immunization of rabbits with cholecystokinin 1-33 resulted in antibodies which can be used in sensitive and specific radioimmunoassays for cholecystokinin.
